Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00870961|
Recruitment Status : Terminated (PI changed institutions and accrual was not completed.)
First Posted : March 27, 2009
Last Update Posted : September 16, 2013
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of vitamin D may keep colorectal cancer from forming in patients with colon polyps.
PURPOSE: This randomized phase I trial is studying a vitamin D supplement to see how well it works compared with a placebo in preventing colorectal cancer in African Americans with colon polyps.
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer Precancerous Condition||Dietary Supplement: cholecalciferol Other: placebo||Not Applicable|
- To determine the accrual rate of African Americans with adenomatous polyps to a 6-month randomized intervention trial comprising supplementation with either cholecalciferol (vitamin D3) or placebo.
- To determine the compliance rates in patients treated with these regimens.
- To compare changes in pre- and post-treatment vitamin D levels in patients treated with these regimens.
- To correlate vitamin D levels with vitamin D modifiers, such as levels of skin pigmentation, dietary vitamin D intake, and sun exposure in this patient population.
OUTLINE: Patients are randomized to 1 of 2 arms.
- Arm I: Patients receive oral cholecalciferol (vitamin D3) supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive oral placebo supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
Patients complete questionnaires about demographics, dietary vitamin D intake, personal history (e.g., ancestry, alcohol and tobacco intake, occupation, height, and weight), medical history (e.g., personal and family history of colorectal cancer and polyps), and ultraviolet radiation exposure.
Blood samples are collected at baseline and at 6 months for correlative laboratory studies. Blood samples are analyzed for vitamin D levels by enzyme immunoassay. Patients also undergo assessment of skin pigmentation in sunprotected and sunexposed areas of skin by reflectance spectrometry at baseline.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study|
|Study Start Date :||February 2009|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2012|
Experimental: Arm I
Patients receive oral cholecalciferol (vitamin D3) supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
Dietary Supplement: cholecalciferol
Placebo Comparator: Arm II
Patients receive oral placebo supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
- Rate of compliance as assessed at 6 months [ Time Frame: Following 6 months of study treatment ]
- Rate of accrual [ Time Frame: After accrual goal is reached ]
- Changes in pre- and post-treatment vitamin D levels [ Time Frame: At baseline and following completion of study treatment ]
- Correlation of vitamin D levels with vitamin D modifiers (e.g., levels of skin pigmentation, dietary vitamin D intake, and sun exposure) [ Time Frame: After completion of study treatment & final colonic biopsy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00870961
|United States, Illinois|
|Robert H. Lurie Comprehensive Cancer Center at Northwestern University|
|Chicago, Illinois, United States, 60611-3013|
|University of Chicago Cancer Research Center|
|Chicago, Illinois, United States, 60637-1470|
|Principal Investigator:||Halla Nimeiri, MD||Robert H. Lurie Cancer Center|